James M. Boyle - 17 Dec 2025 Form 3 Insider Report for Medline Inc. (MDLN)

Reporting relationship
Chief Executive Officer, Director
Issuer ticker
MDLN
Reported as of
17 Dec 2025
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
3
Accepted by SEC
17 Dec 2025, 19:05:24 UTC
Prior SEC filing
06 Mar 2026
Next SEC filing
17 Jun 2026
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Nicole Fritz, Attorney-in-Fact

Key filing fact

James M. Boyle filed Form 3 for Medline Inc. (MDLN) on 17 Dec 2025.

Key facts

  • This page summarizes James M. Boyle's Form 3 filing for Medline Inc. (MDLN).
  • 0 reported transactions and 8 derivative rows are listed below.
  • Accepted by SEC: 17 Dec 2025, 19:05.

Change

  • Previous filing in this sequence was filed on 06 Mar 2026.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Official SEC source

Ownership activity is grounded in SEC Form 3 disclosures.

View source filing

Reporting Owners (1)

CIK 0002061052 Primary reporting owner

Boyle James M

Relationship
Chief Executive Officer, Director
Address
C/O MEDLINE INC., 3 LAKES DRIVE, NORTHFIELD
Signature
/s/ Nicole Fritz, Attorney-in-Fact
Signature date
17 Dec 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

MDLN holding

Class B Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
24,313
Date
17 Dec 2025
Ownership
Direct
Footnotes
F1
MDLN holding

Class B Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
514,876
Date
17 Dec 2025
Ownership
See Footnote
Footnotes
F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

MDLN holding Derivative

Common Units of Medline Holdings, LP

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
17 Dec 2025
Ownership
See Footnote
Underlying class
Class A Common Stock
Underlying amount
24,313
Exercise price
Footnotes
F3
MDLN holding Derivative

Common Units of Medline Holdings, LP

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
17 Dec 2025
Ownership
See Footnotes
Underlying class
Class A Common Stock
Underlying amount
514,876
Exercise price
Footnotes
F2, F3
MDLN holding Derivative

Incentive Units of Medline Holdings, LP

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
17 Dec 2025
Ownership
See Footnote
Underlying class
Class A Common Stock
Underlying amount
1,201,584
Exercise price
$15.42
Footnotes
F4, F5, F6
MDLN holding Derivative

Incentive Units of Medline Holdings, LP

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
17 Dec 2025
Ownership
See Footnote
Underlying class
Class A Common Stock
Underlying amount
340,407
Exercise price
$15.23
Footnotes
F4, F5, F7
MDLN holding Derivative

Incentive Units of Medline Holdings, LP

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
17 Dec 2025
Ownership
See Footnote
Underlying class
Class A Common Stock
Underlying amount
1,146,379
Exercise price
$16.49
Footnotes
F4, F5, F8
MDLN holding Derivative

Incentive Units of Medline Holdings, LP

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
17 Dec 2025
Ownership
See Footnote
Underlying class
Class A Common Stock
Underlying amount
252,481
Exercise price
$19.01
Footnotes
F4, F5, F9
MDLN holding Derivative

Incentive Units of Medline Holdings, LP

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
17 Dec 2025
Ownership
See Footnote
Underlying class
Class A Common Stock
Underlying amount
183,699
Exercise price
$27.68
Footnotes
F4, F5, F10
MDLN holding Derivative

Incentive Units of Medline Holdings, LP

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after
Date
17 Dec 2025
Ownership
See Footnotes
Underlying class
Class A Common Stock
Underlying amount
1,057,309
Exercise price
$15.42
Footnotes
F2, F4, F5, F11
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 11 footnotes

Footnote F1

Shares of the Issuer's Class B common stock ("Class B Common Stock") have no economic value and have one vote per share. One share of Class B Common Stock is issued for each common unit of Medline Holdings, LP ("Common Units") held. Upon an exchange of Common Units for shares of the Issuer's Class A common stock ("Class A Common Stock"), an equivalent number of shares of Class B Common Stock held by such holder will be automatically cancelled.

Footnote F2

These securities are held by a family trust of which the Reporting Person's spouse is the trustee.

Footnote F3

Pursuant to the terms of an exchange agreement, dated as of December 16, 2025 (the "Exchange Agreement"), holders have the right to exchange their Common Units for shares of Class A Common Stock on a one-for-one basis, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. These exchange rights do not expire. Such Common Units are held indirectly through Medline Management Aggregator LLC.

Footnote F4

Reflect incentive units of Medline Holdings, LP ("Incentive Units"), which are "profit interests" having economic characteristics similar to stock appreciation rights. Vested Incentive Units are convertible, at the holder's election, into a number of Common Units generally equal to (a) the product of the number of vested Incentive Units to be converted with a given per unit participation threshold and then-current difference between the per unit value of a Common Unit at the time of the conversion (based on the public trading price of a share of Class A Common Stock) and the per unit participation threshold of such vested Incentive Units divided by (b) the per unit value of a Common Unit at the time of the conversion (based on the public trading price of a share of Class A Common Stock), subject to certain adjustments.

Footnote F5

(Continued from Footnote 4 above) Common Units are exchangeable on a one-for-one basis for shares of Class A Common Stock pursuant to the terms of the Exchange Agreement. These Incentive Units have no expiration date. Such Incentive Units are held indirectly through Medline Management Aggregator LLC.

Footnote F6

62% of these Incentive Units have vested, and the remaining 38% vest on October 21, 2026.

Footnote F7

40% of these Incentive Units have vested, and the remaining 60% vest in three equal annual installments beginning on April 1, 2026.

Footnote F8

40% of these Incentive Units have vested, and the remaining 60% vest in three equal annual installments beginning on October 1, 2026.

Footnote F9

20% of these Incentive Units have vested, and the remaining 80% vest in four equal annual installments beginning on March 29, 2026.

Footnote F10

These Incentive Units vest in five equal annual installments beginning on March 28, 2026.

Footnote F11

These Incentive Units are fully vested.

SEC remarks

Exhibit 24 - Power of Attorney.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .